Kidney Transplantation
Conditions
Keywords
robot-assisted kidney transplantation, ABO incompatible, biopsy-proven acute rejection, immunologically high-risk patients
Brief summary
While robot-assisted kidney transplantation (RAKT) offers potential benefits such as minimal postoperative pain, better cosmesis, fewer wound infections, and shorter hospital stay, its efficacy in ABO-incompatible (ABO-i) KT compared to open KT (OKT) remains understudied. This study aims to compare ABO-i KT outcomes between RAKT and OKT. The study utilized data from 29 ABO-i RAKT and 210 ABO-i OKT cases performed at Asan Medical Center from October 2020 to February 2023. Univariate and multivariate analyses were performed to evaluate factors associated with a composite of biopsy-proven acute rejection (BPAR), de novo donor-specific antibodies (DSA), and overall graft failure.
Interventions
The interventional surgery is a robot-assisted kidney transplantation and its efficacy will be measured against that of open kidney transplantation
Sponsors
Asan Medical Center
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patient eligible for living donor ABO incompatible kidney transplantation * Presenting an IsoAgglutinin immunoglobulin G titer (anti-A-B) between 1/8 and 1/128 before operation * Patient older than 18 years and young than 80 years * Patient able to sign an informed consent form
Exclusion criteria
* Patient with comorbidities or hypersensitivity that prevent desensitization protocols * Women who are pregnant, or who may become pregnant or breastfeeding women * Subjects under legal protection * Subjects participating in another interventional research protocol or in an exclusion period from another interventional research protocolPatient affiliated with a social security scheme
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Graft survival | 1 year post-operative | allograft (kidney) survival |
| renal function | 1 year post-operative | renal function measured in terms of eGFR (Estimated Glomerular Filtration Rate) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| . A composite of biopsy-proven acute rejection, graft failure, and the development of de novo donor-specific antibodies | 1 year post-operative | . A composite of biopsy-proven acute rejection, graft failure, and the development of de novo donor-specific antibodies |
Countries
South Korea
Outcome results
None listed